ArticleTransfusion2026
Serum-derived albumin as a cryoprotective agent for the long-term storage of red blood cells: A preliminary examination.
Article in Transfusion, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundCryopreservation extends the shelf life of red blood cells (RBC) from weeks to years, offering major advantages for blood banking logistics, especially in remote environments. However, current glycerol-based methods, though effective, are limited in scope due to complex post-thaw washing and incompatibility with routine clinical workflows. This study evaluated plasma-derived albumin as a potential alternative cryoprotective agent (CPA) for human RBC. STUDY DESIGN AND
methodsDonor-derived RBC were suspended in 25% w/v bovine serum albumin (BSA) prepared in various diluents and tested for biocompatibility and cryoprotective efficacy under rapid freezing (immersion in liquid nitrogen) and gradual freezing with storage at -80°C. Post-thaw recovery was quantified by measuring hemolysis after resuscitation of frozen cells to 37°C.
resultsAlbumin-based media were non-toxic, maintaining >99% RBC recovery prior to freezing. When rapidly frozen, albumin conferred strong cryoprotection (≥95% recovery) in salt-rich diluents such as SAG-M, Hartmann's, and Alsever's solutions, exceeding that of glycerol-based CPA (77 ± 25%). Albumin's cryopreservative efficacy was enhanced in ionic media of neutral pH but was absent entirely under gradual freezing (<20% recovery). DISCUSSION: The cryoprotective effect of albumin appears dependent on rapid cooling and ionic co-solutes, suggesting a mechanism rooted in colloid-ion interactions rather than direct inhibition of ice formation. The dependence on freeze rate and ionic environment suggests that multiple solution properties contribute to its efficacy. While further work is required to clarify underlying mechanisms, albumin-based methods may provide a basis for a simplified method of cryopreservation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.